Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

24 HR Rotigotine 0.0417 MG/HR Transdermal System

Known as: ROTIGOTINE 1MG/24HRS PATCH [VA Product], rotigotine 1 MG/Day 24HR Transdermal System, ROTIGOTINE 1MG/24HRS PATCH 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
HIGHLIGHTSThe method was validated for selectivity, linearity, precision, accuracy, recovery, matrix effect and stability.The… Expand
  • figure 1
  • table 1
  • table 4
  • table 2
  • figure 3
Is this relevant?
2016
2016
Background and purpose Dopamine agonists in Parkinson's disease (PD) are associated with impulse control disorders (ICDs) and… Expand
  • table 2
  • figure 1
  • table 3
  • figure 2
  • table 4
Is this relevant?
2015
2015
Rotigotine is a nonergoline dopamine agonist which can be used to treat Parkinson’s disease (PD) through a transdermal patch, the… Expand
Is this relevant?
2013
2013
Currently available dopaminergic drugs such as levodopa and dopamine (DA) receptor agonists impart considerable improvement in… Expand
  • figure 1
  • figure 3
  • figure 2
  • table 1
  • figure 4
Is this relevant?
2013
2013
Abstract The transdermally applied dopamine receptor agonist rotigotine is extensively metabolized in the liver. An open-label… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2007
2007
Background and objectiveThe dopamine agonist rotigotine has been formulated in a silicone-based transdermal system for once-daily… Expand
Is this relevant?
2004
2004
AbstractPurpose. The aim of this study was to characterize the influence of pH and NaCl concentration on the transdermal… Expand
  • figure 2
  • table I
  • figure 1
  • table II
  • figure 3
Is this relevant?
Review
2003
Review
2003
  • Hermann Am Mucke
  • IDrugs : the investigational drugs journal
  • 2003
  • Corpus ID: 23171089
Schwarz Pharma AG, under license from Aderis Pharmaceuticals Inc, is developing rotigotine CDS, a once-daily transdermal patch… Expand
Is this relevant?